Synthetic tetrapeptide bioregulator · Fact sheet
Livagen
Also known as Lyvagen · Lys-Glu-Asp-Ala · KEDA peptide
Livagen is a synthetic tetrapeptide studied in cultured lymphocytes, rat hepatocytes and digestive-enzyme experiments. These findings do not establish liver regeneration, detoxification or a human anti-aging treatment.
What is Livagen?
Livagen is Lys-Glu-Asp-Ala in the primary literature.
A peptide designed from analysis of a liver extract is not the same intervention as that tissue-derived mixture.
Benefits & claims
Interest centers on immune and digestive biology, aging and cellular function. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- Lymphocyte experiments reported changes in chromatin organization.
- Rat hepatocyte work reported changes in protein-synthesis patterns; another rat study measured digestive enzymes.
- No human clinical liver or longevity benefit follows from these surrogate measures.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Livagen. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Livagen is Lys-Glu-Asp-Ala in the primary literature.
Formulation differences
- A peptide designed from analysis of a liver extract is not the same intervention as that tissue-derived mixture.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Human organ safety, interactions and pharmacokinetics remain unestablished.
- Resistance to an enzyme in a laboratory does not establish meaningful oral absorption or safety in people.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe evidence is cellular and animal. Cultured cells from older people do not demonstrate that an administered product improves health in older people.
Studies
Cultured human-lymphocyte chromatin experiment.
Rat hepatocyte protein-synthesis experiment.
Rat and laboratory digestive-enzyme study.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Livagen has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people.
- [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
No human clinical liver or longevity benefit follows from these surrogate measures.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedEffects of Livagen peptide on chromatin activation in lymphocytes from old people.
Cultured human-lymphocyte chromatin experiment.
- pubmed[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].
Rat hepatocyte protein-synthesis experiment.
- pubmed[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].
Rat and laboratory digestive-enzyme study.